ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Perrigo Company Plc Ireland

Perrigo Company Plc Ireland (PRGO)

27.83
0.08
( 0.29% )
Updated: 14:17:42

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
27.83
Bid
-
Ask
-
Volume
355,387
27.37 Day's Range 27.8716
24.815 52 Week Range 40.28
Market Cap
Previous Close
27.75
Open
27.79
Last Trade
46
@
27.825
Last Trade Time
14:17:52
Financial Volume
$ 9,850,619
VWAP
27.718
Average Volume (3m)
1,618,041
Shares Outstanding
136,320,433
Dividend Yield
3.95%
PE Ratio
-297.64
Earnings Per Share (EPS)
-0.09
Revenue
4.66B
Net Profit
-12.7M

About Perrigo Company Plc Ireland

Perrigo Co PLC is a leading private label supplier of generic over the counter (OTC) drugs in the U.S. and Europe. The company's product offerings fall under traditional OTC drug categories (i.e. cough, cold, allergy, pain), in addition to oral care, infant nutrition (formula), and nicotine cessatio... Perrigo Co PLC is a leading private label supplier of generic over the counter (OTC) drugs in the U.S. and Europe. The company's product offerings fall under traditional OTC drug categories (i.e. cough, cold, allergy, pain), in addition to oral care, infant nutrition (formula), and nicotine cessation aids. In addition to private label manufacturing, the company also sells products under its own brands (largely in the skincare and oral-care category). The company became a pure-play in OTC consumer healthcare in 2021, following a series of divestitures over several years (sold off generic prescription topicals, animal health, and active pharmaceutical ingredient business). In late 2021, Perrigo signed an offer to acquire HRA Pharma. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Dublin, Irl
Founded
1970
Perrigo Company Plc Ireland is listed in the Pharmaceutical Preparations sector of the New York Stock Exchange with ticker PRGO. The last closing price for Perrigo Company Plc Irel... was $27.75. Over the last year, Perrigo Company Plc Irel... shares have traded in a share price range of $ 24.815 to $ 40.28.

Perrigo Company Plc Irel... currently has 136,320,433 shares outstanding. The market capitalization of Perrigo Company Plc Irel... is $3.78 billion. Perrigo Company Plc Irel... has a price to earnings ratio (PE ratio) of -297.64.

PRGO Latest News

Perrigo to Release Second Quarter 2024 Financial Results on August 2, 2024

Perrigo to Release Second Quarter 2024 Financial Results on August 2, 2024 PR Newswire DUBLIN, July 19, 2024 DUBLIN, July 19, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading...

Perrigo Completes Divestment of HRA Pharma Rare Diseases Business

Perrigo Completes Divestment of HRA Pharma Rare Diseases Business PR Newswire DUBLIN, July 10, 2024 DUBLIN, July 10, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE PRGO) ("Perrigo" or the...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.833.074074074072728.76526.93151616427.66842443CS
41.816.9561875480426.0228.76524.815143938726.7420333CS
12-4.96-15.126562976532.7933.45524.815161804128.11006316CS
26-5.92-17.540740740733.7533.9624.815177823529.19840448CS
52-7.49-21.206115515335.3240.2824.815167728330.62723163CS
156-18.18-39.513149315446.0151.0924.815151132235.59186063CS
260-24.85-47.17160212652.6865.124.815135133239.9259573CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
DCAPUnity Wealth Partners Dynamic Capital Appreciation & Options ETF
 20.10
(839.25%)
128.77k
RGCRegencell Bioscience Holdings Ltd
$ 18.88
(460.24%)
615.19k
SLRXSalarius Pharmaceuticals Inc
$ 3.09
(100.65%)
56.86M
CJETChijet Motor Company Inc
$ 6.11
(86.85%)
544.74k
ATPCAgape ATP Corporation
$ 0.2426
(69.65%)
101.82M
FLYEFly E Group Inc
$ 1.29
(-79.78%)
16.43M
RNAZTransCode Therapeutics Inc
$ 0.30
(-62.15%)
8.01M
JAGXJaguar Health Inc
$ 1.77
(-58.55%)
14.09M
MIRAMIRA Pharmaceuticals Inc
$ 2.5701
(-48.70%)
23.6M
IVPInspire Veterinary Partners Inc
$ 6.3676
(-31.09%)
1.11M
SPWRSunPower Corporation
$ 1.085
(51.58%)
161.31M
ADILAdial Pharmaceuticals Inc
$ 1.425
(34.43%)
155.96M
SLNASelina Hospitality PLC
$ 0.0257
(-30.54%)
129.83M
NVDANVIDIA Corporation
$ 122.765
(-0.63%)
121.73M
ATPCAgape ATP Corporation
$ 0.2426
(69.65%)
101.82M

PRGO Discussion

View Posts
slicknick617 slicknick617 1 year ago
Just got its over the counter birth control FDA approved a half hour ago !!!
πŸ‘οΈ0
52wkhi 52wkhi 3 years ago
Thanks PRGO
πŸ‘οΈ0
52wkhi 52wkhi 3 years ago
41.75 afterhours purchase
πŸ‘οΈ0
52wkhi 52wkhi 3 years ago
afterhours purchase above the high of the day
πŸ‘οΈ0
CannabiNERD CannabiNERD 4 years ago
Why would this company invest in Kazmira?
πŸ‘οΈ0
JWard99 JWard99 7 years ago
Dividend helps starboard, but hurts the rest of the shareholders.....nobody is in this for a dividend! We want growth and profits
πŸ‘οΈ0
nonsequetor nonsequetor 7 years ago
***NEWS OUT***

http://ih.advfn.com/p.php?pid=nmona&article=75174311&symbol=PRGO

Perrigo Launches The Generic Version Of Axiron® Topical Solution

DUBLIN, July 5, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced the prescription pharmaceutical launch of testosterone topical solution, 30 mg/1.5 mL (CIII), the generic equivalent to Eli Lilly and Company's Axiron® Topical Solution, 30 mg/1.5 mL (CIII).

Axiron® Topical Solution, 30 mg/1.5 mL (testosterone topical solution, 30 mg/1.5 mL) is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone. Annual market sales for the 12 months ending April 2017 were approximately $248 million.

Perrigo Executive Vice President and President Rx Pharmaceuticals John Wesolowski stated, "This is our third new product launch in the last two weeks. These new product launches illustrate our continued focus on developing and bringing to market important treatments in prescription extended topical therapeutic categories. The Rx team remains committed to investing in complex topical products and to launching more than five new products by the end of 2017."

About Perrigo

Perrigo Company plc, a leading global healthcare company, delivers value to its customers and consumers by providing Quality Affordable Healthcare Products®. Founded in 1887 as a packager of home remedies, Perrigo has built a unique business model that is best described as the convergence of a fast-moving consumer goods company, a high-quality pharmaceutical manufacturing organization and a world-class supply chain network. Perrigo is the world's largest manufacturer of over-the-counter ("OTC") healthcare products and supplier of infant formulas for the store brand market. The Company also is a leading provider of branded OTC products throughout Europe and the U.S., as well as a leading producer of "extended topical" prescription drugs. Perrigo, headquartered in Ireland, sells its products primarily in North America and Europe, as well as in other markets, including Australia, Israel and China. Visit Perrigo online at (http://www.perrigo.com).

Forward-Looking Statements

Certain statements in this press release are "forward-looking statements." These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or the negative of those terms or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control, including: the timing, amount and cost of any share repurchases; future impairment charges; customer acceptance of new products; competition from other industry participants, some of whom have greater marketing resources or larger market shares in certain product categories than we do; pricing pressures from customers and consumers; potential third-party claims and litigation, including litigation relating to our restatement of previously-filed financial information; potential impacts of ongoing or future government investigations and regulatory initiatives; general economic conditions; fluctuations in currency exchange rates and interest rates; the consummation of announced acquisitions or dispositions, and our ability to realize the desired benefits thereof; our ability to achieve our guidance; our ability to execute and achieve the desired benefits of announced cost-reduction efforts and other initiatives; and the timing and expense to complete the announced tender offer for certain of our outstanding notes. In addition, the Company may identify and be unable to remediate one or more material weaknesses in its internal control over financial reporting. Furthermore, the Company and/or its subsidiaries may incur additional tax liabilities in respect of 2016 and prior years as a result of any restatement or may be found to have breached certain provisions of Irish company legislation in respect of prior financial statements and if so may incur additional expenses and penalties. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended December 31, 2016, as well as the Company's subsequent filings with the United States Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
πŸ‘οΈ0
nonsequetor nonsequetor 7 years ago
I came in @.656 on the 24th...

One month later...

NICE!
πŸ‘οΈ0
nonsequetor nonsequetor 7 years ago
You can't ask for a nicer progression upward!
πŸ‘οΈ0
nonsequetor nonsequetor 7 years ago
Chart:

πŸ‘οΈ0
nonsequetor nonsequetor 7 years ago
Indicators poised for the next leg up...
πŸ‘οΈ0
nonsequetor nonsequetor 7 years ago
PRGO...

catching her breath...

πŸ‘οΈ0
nonsequetor nonsequetor 7 years ago
Up... up... up...

Nice rise from .656 !!

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=130821920











πŸ‘οΈ0
nonsequetor nonsequetor 7 years ago
This is the kind of price action one likes to see...

slow and steady, with a little taken off the top from time to time...

and then...

reestablishing the climb...
πŸ‘οΈ0
nonsequetor nonsequetor 7 years ago
NICE!

πŸ‘οΈ0
nonsequetor nonsequetor 7 years ago
Best Dividend Paid in Over a Dozen Years!

http://ih.advfn.com/p.php?pid=nmona&article=74489043&symbol=PRGO
πŸ‘οΈ0
nonsequetor nonsequetor 7 years ago
Nice, steady, upward movement for PRGO!
πŸ‘οΈ0
nonsequetor nonsequetor 7 years ago
The stock has traded between $111.00 and $65.47 over the last 52-weeks, its 50-day SMA is now $72.19, and its 200-day SMA $83.38. Perrigo Company plc has a P/B ratio of 1.12
πŸ‘οΈ0
nonsequetor nonsequetor 7 years ago
8-k Out

http://ih.advfn.com/p.php?pid=nmona&article=74417839&symbol=PRGO

Item of interest:

On April 7, 2017, the Company issued a notice of redemption to redeem all of the $600.0 million in aggregate principal amount of the outstanding 2.300% senior notes due 2018 (the β€œ2.300% 2018 Notes”). The Company expects to redeem all of the 2.300% 2018 Notes on May 8, 2017 using proceeds from the sale of Tysabri

πŸ‘οΈ0
nonsequetor nonsequetor 7 years ago
Perrigo Reaches Agreement With Auditor Over Royalty Accounting
Dublin drugmaker to restate financial statements as far back as Dec. 28, 2013

https://www.wsj.com/articles/perrigo-reaches-agreement-with-auditor-over-royalty-accounting-1493167564

Nice Timing!

**SMILES**
πŸ‘οΈ0
nonsequetor nonsequetor 7 years ago
Daily volume doubling yesterday and already today...

Something in the works???
πŸ‘οΈ0
nonsequetor nonsequetor 7 years ago
Nice upward movement in the past 2 days!

I came in @.656 on the 24th...

Let's see where this goes...
πŸ‘οΈ0
nonsequetor nonsequetor 7 years ago
At a more than 50% discount, PRGO looks quite appetizing.
πŸ‘οΈ0
nonsequetor nonsequetor 7 years ago
Anything new to get excited about?

IS Perrigo still, in your opinion, a buyout candidate, or perhaps, would they consider another alternative if their conditions cannot be met?
πŸ‘οΈ0
nonsequetor nonsequetor 7 years ago
Anything in the wind?

*SNIFF* *SNIFF*
πŸ‘οΈ0
nonsequetor nonsequetor 7 years ago
PRGO moving upward slowly...

πŸ‘οΈ0
nonsequetor nonsequetor 7 years ago
3 Month PRGO Chart

Looking up...

πŸ‘οΈ0
trendmkr trendmkr 7 years ago
Facebook Inc (NASDAQ:FB) Introduces New β€˜Dislike’ Reaction Button On Messenger https://marketexclusive.com/facebook-inc-nasdaqfb-introduces-reaction-button-feature-messenger/79228/?icd1
πŸ‘οΈ0
asmarterwookie asmarterwookie 7 years ago
Try Peregrine $PPHM. Avid Bioservices can even make biosimilars for you....




wook
πŸ‘οΈ0
millionaireonpaper millionaireonpaper 8 years ago
This has been a welcomed couple of days. I've owned this since 2011 and will continue to own this through at least the next couple of years.
πŸ‘οΈ0
VanWilder VanWilder 8 years ago
GSK consumer unit off the table it appears - http://www.telegraph.co.uk/business/2016/09/20/glaxosmithkline-names-emma-walmsley-to-replace-sir-andrew-witty/

Perrigo is becoming the Best viable option for several companies to acquire if they wish to expand in the US generics category.

We should get some meaningful news with PRGO soon


LONG PRGO.
πŸ‘οΈ0
VanWilder VanWilder 8 years ago
PRGO - I'm buying the Rumor here, and settling in for the Long Haul

Van
πŸ‘οΈ0
VanWilder VanWilder 8 years ago
PRGO - Reckitt Benckiser Buyout Potential


Pretty quiet here for a company that may get bought anytime....literally any Day. The puzzle pieces are fitting together way too well to be just a coincidence.


Timeline:

Back in 2015 Mylan tried to go hostile for Perrigo at a $180+ price tag, but did not succeed.

June of 2016 - Rumor hits the street of a Mystery UK buyer for PRGO at the $20B level.

July of 2016 - Rumor hits again that the UK buyer is Reckitt Benckiser of the UK, and preparing a $20B offer.

September 11th 2016 - Activist Starboard Value LP takes a 4.6% stake in PRGO, Advocating several actions within the company to Unlock Shareholder value.


Reckitt Benckiser has publicly looked at buying both Merek's Consumer health division, and Pfizer's Consumer division, but both of these are now off the table. Merek's sold to Bayer, and Pfizer is not breaking up the company until at least 2018. The Pfizer news just came out 6-days ago, so until then BR may have been waiting to see if that was a Viable option. Now it is not. There are far Fewer matches for RB now, than were possibly on the Table in 2014-2015. The clock is ticking for RB to make a move, and I think that they may make a bid for Perrigo before the new year.

My guess is RB has been kicking the Tires on Perrgio now for several months (since at least June), and waiting to see where the Dust settled on the Pfizer Breakup. RB was also mentioned as a buyer for Church & Dwight this Mayy, but those Rumors were Denied by Church & Dwight.

The last Rumor in June of this year even stated the financial Firms advising both PRGO and RB. This Seems awfully specific for an unfounded Rumor, and the June Rumor actually supports the RB theory, and the July story as well. Both Reckitt and Perrigo did NOT deny these Rumors.

Last month, a report claimed Perrigo was close to an agreement to be bought by a UK-based company for $US20bn, although it did not name the latter.

The report in StreetInsider.com cited a source as saying Morgan Stanley (NYSE:MS) was advising Perrigo and Barclays PLC (LON:BARC) was among institutions advising the UK company.


Reckitt Benckiser has been on the Acquisition hunt since at least 2014 to expand their Consumer Health division. They have not Purchased anything yet that fulfills that Goal.

RB CEO:
RB’s net debt ratio of 0.7 times adjusted earnings before interest, tax, depreciation and amortization is below that of competitors Unilever at 1.1 and Procter & Gamble Co. at 1.3, meaning the company has financial flexibility to pursue transformational acquisitions. Discussing firepower, Kapoor said that RB is not thinking about limitations on the size of a potential deal.

β€œIf any of the interesting consumer-health assets were to come up today, I believe RB has the capacity to do it. Any of them,” he said.


With PRGO stock trading at $93 from a High of $200, with a shareholder base that is Angry regarding the slump in Stock Value, Perrigo is Ripe for a takeover bid in the $135-$160 range. The Rumor articles state that Perrigo is looking for a minimum of a 100% premium, but I don't believe if RB or another acquirer made their offer Public, it would take that elevated Premium to get it accomplished. With Starboard coming on board in the past 3-weeks, the Board and newer CEO will be under tremendous pressure to get the Share Price UP, and seriously consider any/all Major moves that may be good for the Stock Price.


Option Volume has been slightly unusual 3 days the past week, with Call Volume above normal, and directionally Bullish Action.

I continue to Add the Nov and Jan PRGO call options, along with the PRGO common stock which is Cheap whether the Perrigo Buyout with Reckitt occurs or not.

LONG PRGO !!!!!!!!!


Links:

http://www.fiercepharma.com/pharma/perrigo-up-for-20b-sale-to-mystery-u-k-buyer-report

http://www.proactiveinvestors.com/companies/news/128264/reckitt-benckiser-set-to-bid-for-perrigo-rumours-128264.html

http://www.modernhealthcare.com/article/20160926/NEWS/160929928

http://www.bloomberg.com/news/articles/2015-12-04/reckitt-benckiser-ceo-would-look-at-buying-pfizer-consumer-unit

http://www.fiercepharma.com/m-a/reckitt-benckiser-gives-up-on-merck-otc-deal-leaving-bayer-open-shot


http://www.cnbc.com/2016/05/19/church-dwight-shares-spike-amid-report-of-reckitt-benckiser-takeover-bid.html

http://thefly.com/news.php?symbol=PRGO


http://247wallst.com/healthcare-business/2015/06/01/3-specialty-pharma-stocks-that-could-be-acquired-in-2015/

πŸ‘οΈ0
VanWilder VanWilder 8 years ago
Pfizer Drops plan to Breakup Company - PRGO on Deck for Reckitt

With Pfizer announcing plans that they will no longer breakup their Consumer Health division, another viable option for Reckitt has been taken off the table. My guess is they have been kicking the tires on both options for several months. In my estimation, there are fewer and fewer Consumer Health Divisions that fit the bill that Benckiser is looking to acquire.

This move may entice them to act, now that the other Potential target is off the table until at least 2018.

PRGO is in the Cross-hairs for them IMO :)

See Below.


http://www.iol.co.za/business/international/pfizer-drops-plan-to-break-up-company-2073247

http://www.bloomberg.com/news/articles/2015-12-04/reckitt-benckiser-ceo-would-look-at-buying-pfizer-consumer-unit

πŸ‘οΈ0
VanWilder VanWilder 8 years ago
PRGO - I believe we get Big News here within a couple weeks. The UK buyer rumor is True in my Mind. Loading Call Options for Nov-Jan for a Big move UP. Options are trading TOO CHEAP for the buyout potential here.

Pretty Quiet on the Web about this stock.....I am surprised by that.

Van
πŸ‘οΈ0
VanWilder VanWilder 8 years ago
I'm adding PRGO here. The stock is undervalued, and I believe the Takeover chatter from June and July is legitimate. The time for a buyer to strike is now while the stock is cheap, and the sector is experiencing major consolidation. A Perrigo Buyout is definitely a possibility. Reckitt Benckiser seems like a Good guess in my mind, as they have been on the Hunt for months, and picked up nothing major. Perrigo is a good fit for Reckitt

With Starboard taking a stake here, I think PRGO will have positive news within the next 4-weeks either way. They will make the BOD and Directors Unlock the True value of Perrigo. Adding PRGO Call Options and Perrigo Stock Daily.


Van
πŸ‘οΈ0
T695 T695 8 years ago
Reaction??
πŸ‘οΈ0
Impacto Impacto 8 years ago
Interesting here :)
πŸ‘οΈ0
wagner wagner 8 years ago
Nuts... High book value and earnings and fantasy for big bid to be sold to a great player
Tztztz...
πŸ‘οΈ0
wagner wagner 8 years ago
Thanks

For you the same, did my "steals" yesterday,

Cheers
πŸ‘οΈ0
djpope djpope 8 years ago
Always very quiet here only 20 posts in last 4 years

Seems like a great entry point at this level, pretty much at 2012/2013 lows and close to 50% off 52 week high.

I would say Up is the only direction to go from here as IMO selling was way overdone & really no major "issues".

Best to you. dp

πŸ‘οΈ0
wagner wagner 8 years ago
Very silent here,
people waiting for better prices or a new offer to take from
a other pharma leading company
πŸ‘οΈ0
wagner wagner 8 years ago
Valued 8times earnings, middel should be 20times,
Intersting weeks coming up, paying a div.
πŸ‘οΈ0
wagner wagner 8 years ago
Touch down. ;-()

Brought some 100,45

Rebound is not far away and maybe some buy out stories in the
Coming weeks
πŸ‘οΈ0
ClarkKant ClarkKant 8 years ago
Certainly looks that way lol looks like it was settling then the west coast effect took it down another $3 lol.
πŸ‘οΈ0
Tradescott818 Tradescott818 8 years ago
Going to zero
πŸ‘οΈ0
ClarkKant ClarkKant 8 years ago
Wow, heading under $100?
πŸ‘οΈ0
ash111 ash111 8 years ago
why the big drop past days?
πŸ‘οΈ0
DewDiligence DewDiligence 9 years ago
MYL commences tender offer for PRGO: #msg-116951856.
πŸ‘οΈ0
DewDiligence DewDiligence 9 years ago
MYL shareholder vote on PRGO deal scheduled for 8/28/15:

http://finance.yahoo.com/news/mylan-announces-meeting-date-record-195800002.html
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock